Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rabin Rahmani

Gastroenterology Brooklyn, NY Medical Doctor

NPI 1457514044 CMS profile 338780

1723 E 12Th St, Brooklyn, NY 11229

Open in the dashboard

General payments

$155,259

399 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rabin Rahmani of Brooklyn, NY is reported in the CMS Open Payments database as having received $155,259 across 399 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,540 43
2024 General $17,016 64
2023 General $21,291 58
2022 General $35,956 80
2021 General $43,207 79
2020 General $6,891 28
2019 General $16,358 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rabin Rahmani
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Rabin Rahmani were reported at $14,540. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Rabin Rahmani Gastroenterology median Middle half National median
2019 $16,358 $417 $126–$1,100 $163
2020 $6,891 $224 $74–$624 $114
2021 $43,207 $352 $106–$1,054 $132
2022 $35,956 $448 $129–$1,270 $149
2023 $21,291 $533 $150–$1,390 $160
2024 $17,016 $605 $160–$1,606 $164
2025 $14,540 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $83,267 57 payments
  2. AbbVie, Inc. $32,808 134 payments
  3. Phathom Pharmaceuticals, Inc. $23,508 24 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $10,195 33 payments
  5. Celgene Corporation $2,710 57 payments
  6. Gilead Sciences, Inc. $544 18 payments
  7. Pfizer Inc. $305 13 payments
  8. Janssen Biotech, Inc. $241 6 payments
  9. Intra-Sana Laboratories $160 3 payments
  10. UCB, Inc. $152 3 payments
  11. Other $1,370 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $130,809 49 payments
  2. Food and Beverage $9,983 335 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $9,600 4 payments
  4. Travel and Lodging $2,451 5 payments
  5. Consulting Fee $2,400 5 payments
  6. Education $16 1 payment
Products named General payments · program years 2019–2025
  1. ZEPOSIA $84,026 106 payments
  2. VOQUEZNA $23,486 21 payments
  3. HUMIRA $14,325 30 payments
  4. RINVOQ $12,501 35 payments
  5. XIFAXAN $5,119 21 payments
  6. TRULANCE $2,586 9 payments
  7. PLENVU $2,450 2 payments
  8. MAVYRET $384 39 payments
  9. XELJANZ $305 13 payments
  10. CREON $289 19 payments
  11. Other $3,644 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

778

Median for Gastroenterology: 569

Drug cost

$159,954

Median for Gastroenterology: $104,976

Branded share of claims

43.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 13 $59,912
Voquezna Vonoprazan Fumarate Brand 44 $33,909
Trulance Plecanatide Brand 24 $24,426
Linzess Linaclotide Brand 33 $23,888
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 122 $7,316
Dexlansoprazole Dr Dexlansoprazole Brand 26 $6,349
Pantoprazole Sodium Generic 249 $1,617
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 58 $800
Famotidine Generic 65 $369
Omeprazole Generic 61 $352

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$139,558

Medicare's payments for the services billed

Medicare patients

399

Average age 72

Services billed

1,310

212 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 45%
Ischemic heart disease 28%
Heart failure 18%
Chronic kidney disease 17%
Cancer 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $9,745
$9,745 44 —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $5,916
  • Celgene Corporation $793
$6,709 — —
RINVOQ
  • AbbVie, Inc. $92
$92 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $89
$89 — —
SKYRIZI
  • AbbVie, Inc. $68
$68 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

399 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record